Cramer's Latest Stock Picks: Endorsing Vistra and Stryker, Sidestepping AI-Sensitive FICO
Money

Cramer's Latest Stock Picks: Endorsing Vistra and Stryker, Sidestepping AI-Sensitive FICO

authorBy Natalie Pace
DateJun 18, 2026
Read Time2 min

Financial markets are constantly evolving, and investors often look to seasoned experts for guidance. In a recent segment, renowned financial analyst Jim Cramer offered his current perspectives on several key stocks, endorsing Vistra and Stryker, while advising caution on Fair Isaac Corporation (FICO) due to potential disruptions from artificial intelligence.

Market Analyst's Insights: Stock Recommendations and Performance Metrics

On June 18, 2026, during the "Mad Money Lightning Round" on CNBC, esteemed financial commentator Jim Cramer provided his updated investment recommendations. He expressed confidence in Vistra Corp. (NYSE: VST), noting its recent price adjustment and giving it his "blessing." Vistra had previously reported strong first-quarter GAAP net income of $1.029 million, with Adjusted EBITDA from ongoing operations reaching $1,494 million, figures released on May 7.

Regarding Stryker (NYSE: SYK), Cramer acknowledged his prior expectation of consolidation within the industry, with Stryker leading such efforts, although this has yet to materialize. Despite this, he maintained his positive stance on the medical technology firm. Leerink Partners analyst Mike Kratky echoed a similar sentiment on June 5, reaffirming an Outperform rating for Stryker, albeit with a slight price target reduction from $410 to $407.

Conversely, Cramer voiced reservations about Fair Isaac Corporation (NYSE: FICO), citing concerns about its vulnerability to advancements in artificial intelligence. He articulated a clear strategy to avoid companies potentially impacted by AI, describing it as "too painful" a risk. This cautious approach came shortly after Fair Isaac announced a substantial $2 billion share buyback program on June 8. Meanwhile, on June 11, UBS analyst Jonathan Yong adjusted the price target for Clover Health Investments from $2.75 to $4.75, while maintaining a Neutral rating.

The market witnessed varied reactions among these stocks on Wednesday. Fair Isaac shares experienced a 5% decline, settling at $1,126.84. Clover Health Investments also saw a decrease, falling 2.8% to close at $4.80. In contrast, Vistra shares registered a modest gain of 0.1%, closing at $158.83, while Stryker shares decreased by 3% to $301.14.

Cramer's insights serve as a reminder of the complex interplay between company fundamentals, market sentiment, and technological advancements. His discerning approach to AI's impact on various sectors underscores the need for investors to carefully consider long-term trends alongside immediate financial performance. The mixed performance of the discussed stocks highlights the dynamic and often unpredictable nature of the equities market, urging investors to conduct thorough due diligence and align their strategies with well-informed expert opinions.

More Articles
Money
AP Moller Capital Acquires Mainstream Renewable Power South Africa
AP Moller Capital, through its Emerging Markets Infrastructure Fund II, has finalized an agreement to purchase Mainstream Renewable Power South Africa. This strategic acquisition will transfer ownership of the South African renewable energy developer and independent power producer to the fund, marking a significant step in expanding its clean energy portfolio in emerging markets.
By JL CollinsJun 18, 2026
Money
Investment Firm Highlights Pennant Group Amidst Healthcare Tailwinds
Turtle Creek Asset Management's Q1 2026 report emphasizes their investment in The Pennant Group, Inc. (PNTG), a healthcare company specializing in home health and hospice services. The firm praises Pennant's decentralized operational model, fostering local leadership and high-quality patient care. Despite increased market volatility and AI-related trades, Pennant's shares have shown significant growth over the past year.
By JL CollinsJun 18, 2026
Money
Netflix Stock: An Undervalued Opportunity Despite Market Skepticism
Despite recent stock declines and market skepticism regarding growth slowdowns, Netflix (NFLX) is trading at its lowest valuation in four years. Futurum Equities' Shay Boloor highlights the streaming giant's strong execution, evidenced by double-digit revenue and operating income growth, coupled with increasing pricing power. The company's strategic focus on optimizing content and advertising through AI, alongside the rapid expansion of its ad-supported tier and live sports offerings, positions it for significant future gains, presenting a compelling opportunity for investors.
By Bola SokunbiJun 18, 2026
Money
EU Chief Advocates for US-Europe AI Alliance Amid Sovereignty Concerns
European Commission President Ursula von der Leyen has urged for a stronger transatlantic alliance on artificial intelligence during a G7 session. She highlighted the immense potential and serious risks of AI, advocating for joint investment and cooperation between Europe and the U.S. to shape its future direction. This call comes as Europe grapples with growing concerns over AI sovereignty and dependence on foreign AI providers.
By Vicki RobinJun 18, 2026
Money
Euro Tech Holdings Experiences Significant After-Hours Stock Surge
Euro Tech Holdings' stock (CLWT) soared over 12% in after-hours trading, following an impressive intraday gain. This substantial rise is attributed to the company's strategic partnership with Sea Clean AS, aimed at expanding its advanced ballast water treatment solutions into the European market, starting with Norway.
By Vicki RobinJun 18, 2026